Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BRISTOL-MYERS CVR INVESTORS: December 6, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser

10/22/2021 | 03:56pm EST

The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed against Bristol-Myers Squibb Company (“Bristol-Myers” or the “Company”) on behalf of former shareholders of Celgene Corporation (“Celgene”) (Nasdaq: CELG) who received Contingent Value Rights (“CVRs”) (NYSE: BMY.RT) in exchange for their shares pursuant to Bristol-Myers’s $74 billion acquisition of Celgene on November 20, 2019 (“Merger”).

If you are a former Celgene shareholder who acquired CVRs in exchange for your Celgene shares pursuant to the Merger, you may move the Court for appointment as lead plaintiff by no later than December 6, 2021. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.

Bristol-Myers CVR holders who wish to learn more about the litigation and how to seek appointment as lead plaintiff should click here, or text or email investorinfo@lchb.com, or call Sharon M. Lee of Lieff Cabraser at 1-800-541-7358.

Background on the Bristol-Myers Securities Class Litigation

Bristol-Myers, headquartered in New York City, is one of the world’s largest pharmaceutical companies.

The action arises from Bristol-Myers’s alleged subversion of the Food and Drug Administration (“FDA”) approval process for a cancer therapy known as “Liso-cel” in order to avoid paying $6.4 billion to CVR holders. The CVR payout required FDA approval of three therapies, including Liso-Cel, by specified dates (the “Milestones”).

The action alleges that defendants made materially false and misleading statements and omissions of material facts in the Joint Proxy filed with the Securities and Exchange Commission in connection with the Merger. The Joint Proxy stated that upon completion of the Merger, Celgene shareholders would receive CVRs that could be exchanged for payment of $9.00 per share upon completion of certain “Milestones.” One of the Milestones was obtaining FDA approval for Liso-cel by December 31, 2020. To avoid paying CVR holders, Bristol-Myers made defective filings to the FDA to ensure delay in the FDA’s review, inspection and approval of Liso-cel, which caused it to miss the Liso-cel Milestone. Accordingly, defendants’ statements in the Joint Proxy concerning the efforts Bristol-Myers would make to meet the Milestones, the likelihood that the Milestones would be met and the purported value of the CVRs were materially false and misleading when made.

About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, and Nashville, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

The National Law Journal has recognized Lieff Cabraser as one of the nation’s top plaintiffs’ law firms for fourteen years. In compiling the list, the National Law Journal examines recent verdicts and settlements and looked for firms “representing the best qualities of the plaintiffs’ bar and that demonstrated unusual dedication and creativity.” Law360 has selected Lieff Cabraser as one of the Top 50 law firms nationwide for litigation, highlighting our firm’s “laser focus” and noting that our firm routinely finds itself “facing off against some of the largest and strongest defense law firms in the world.” Benchmark Litigation has named Lieff Cabraser one of the “Top 10 Plaintiffs’ Firms in America.”

For more information about Lieff Cabraser and the firm’s representation of investors, please visit https://www.lieffcabraser.com/.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

ę Business Wire 2021
11/29BRISTOL-MYERS SQUIBB : Deucravacitinib Applications Advance in U.S., Europe
11/29Bristol-Myers Squibb Files New Drug Application With US FDA, Marketing Authorization Wi..
11/29Bristol Myers Squibb's Applications for Deucravacitinib for the Treatment of Moderate t..
11/29Bristol Myers Squibb Announces Approval for Applications for Deucravacitinib for Treatm..
11/24INSIDER SELL : Bristol Myers Squibb
11/23Bristol Myers Squibb Gets EU Marketing Approval For Ulcerative Colitis Drug Zeposia
11/23Bristol Myers Gets Europe OK for Zeposia in Ulcerative Colitis
11/23Bristol-Myers Squibb's Ulcerative Colitis Drug Zeposia Gets European Approval
11/23Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for us..
11/23Bristol-Myers Squibb Company Receives European Commission Approval of Zeposia for Use i..
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Financials (USD)
Sales 2021 46 403 M - -
Net income 2021 6 791 M - -
Net Debt 2021 26 388 M - -
P/E ratio 2021 18,1x
Yield 2021 3,67%
Capitalization 119 B 119 B -
EV / Sales 2021 3,13x
EV / Sales 2022 2,85x
Nbr of Employees 30 250
Free-Float 75,9%
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | BMY | US1101221083 | MarketScreener
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 53,63 $
Average target price 72,53 $
Spread / Average Target 35,2%
EPS Revisions
Managers and Directors
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Executive VP
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON1.16%420 557
ROCHE HOLDING AG15.70%334 662
PFIZER, INC.42.35%294 114
NOVO NORDISK A/S67.75%247 392